GU Cancers 2025 | The potential applications of ctDNA in renal cell carcinoma

Simpa Salami • 20 Feb 2025

GU Cancers 2025

Simpa Salami, MD, MPH, University of Michigan, Ann Arbor, MI, suggests further data is required prior to implementing circulating tumor DNA (ctDNA) in renal cell carcinoma (RCC). Whilst ctDNA could theoretically inform on early detection, disease relapse and monitoring treatment processes, and has been detected in patients before and after surgery in some studies, implementation to precision medicine requires further trials. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.